Loading...
•
Dec 31, 2020
Insulet Q4 2020 Earnings Report
Insulet reported an 18% increase in revenue for Q4 2020, marking the 5th consecutive year of over 20% revenue growth.
Key Takeaways
Insulet Corporation reported a strong finish to 2020 with an 18% increase in revenue for the fourth quarter, reaching a record quarterly revenue of $246.1 million. The company also celebrated a milestone of 250,000 global customers using the Omnipod System.
Q4 2020 revenue increased by 17.5% to $246.1 million.
Total Omnipod revenue increased by 20.1% to $231.1 million.
U.S. Omnipod revenue increased by 17.8% to $149.2 million.
International Omnipod revenue increased by 24.5% to $81.9 million.
Insulet
Insulet
Insulet Revenue by Segment
Revenue by Segment
U.S. Omnipod Revenue
CapyFin.comInternational Omnipod Revenue
CapyFin.comDrug Delivery Revenue
CapyFin.com Forward Guidance
For the year ending December 31, 2021, the Company expects revenue growth in the range of 15% to 20%. For the quarter ending March 31, 2021, the Company expects revenue growth of 20% to 24%.
Positive Outlook
- Total Omnipod of 17% to 21%
- U.S. Omnipod of 21% to 25%
- International Omnipod of 10% to 15%
- Drug Delivery of (11)% to 4%
- Operating margin in the low double digits range.
Revenue & Expenses
Visualization of income flow from segment revenue to net income